Wandiz-LC Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic idiopathic urticaria. Levocetirizine is a potent, selective second-generation antihistamine that effectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, rhinorrhea, nasal itching, and urticaria with minimal sedation. Montelukast is a selective leukotriene receptor antagonist that blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction, mucus secretion, and airway edema, making it beneficial in controlling asthma symptoms and allergic rhinitis. The combination therapy provides a synergistic effect by targeting multiple pathways involved in allergic inflammation, improving symptom control and patient compliance. Wandiz-LC is typically administered once daily, with or without food, as prescribed by a healthcare professional. It is generally well-tolerated; however, potential side effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. Wandiz-LC Tablet should be used under medical supervision, with dosage adjustments based on individual patient response and clinical condition.